Cytotoxicity Effects of Mouse IgG Produced against Three Nanoliposomal Human DR5 Receptor Epitopes on Breast Cancer Cells |
Amirijavid, Shaghayegh
(Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University)
Entezari, Maliheh (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) Movafagh, Abolfazl (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) Hashemi, Mehrdad (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) Mosavi-Jarahi, Alireza (Department of Epidemiology, School of Medicine, Shahid Beheshti University of Medical Sciences) Dehghani, Hossein (Department of Medical laboratory Sciences, Tehran Medical Sciences Branch, Islamic Azad University) |
1 | Almasan A, Ashkenazi A (2003). Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev, 14, 337-48. DOI |
2 | Amirijavid S, Hashemi M (2015). Detection of anticancer and apoptotic effect of the produced IgYs against the three extracellular domain of human DR5 protein. Iran J Cancer Prev, 8,109-15. |
3 | Amirijavid S, Hashemi M (2014). Anticancer effect of the IgY that produced against a small peptide with 15 amino acids of human DR5 on MCF7 cell line. JPS, 5,1-6. |
4 | Ashkenazi A (2002). Targeting death and decoy receptors of the tumor necrosis factor superfamilly. Nat Rev Cancer, 2, 420-300. DOI |
5 | Bellail AC, Qi L, Mulligan P, et al (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials, 4, 34-41. DOI |
6 | Benedict CA, Banks TA, et al. (2003). Death and survivel: viral regulation of TNF signaling pathways.Curr Opin Immunol, 15, 59-65. DOI |
7 | Bodmer JL, Schneider P, et al (2002). The molecular architecture of the TNF superfam.Trends. Biochem Sci, 27,19-26. DOI |
8 | Cha SS, Sung BJ, et al. (2000). Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J BiolChem, 275, 31171-7. |
9 | Chaudhary PM, Eby M, et al (1997). Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa B pathway. Immunity,7,821-30. DOI |
10 | Heidari MH, Porghasem M, Mirzaei N, et al (2014). The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran. J Environ Radioact, 128, 64-7. DOI |
11 | Gajewski TF (2007). On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol, 25,1305-7. DOI |
12 | Ichikawa K, Liu W, et al (2001). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med,7, 954-60. DOI |
13 | Kelley RF, Totpal K, et al (2005). Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J BiolChem, 280, 2205-12. |
14 | Mahalingam D, Szegezdi E, et al (2009). TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treat Rev, 35, 280-8. DOI |
15 | Mori E, Thomas M, et al (2004). Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ, 11, 203-7. DOI |
16 | Movafagh A, Hajifathali A, Zamani M (2011). Secondary chromosomal abnormalities of de novo acute myeloid leukemia-a first report from the Middle East. Asian Pac J Cancer Prev, 12, 2991-4. |
17 | Movafagh A, Mirfakhraei R, Mousavi-Jarrahi A (2011). Frequent incidence of double minute chromosomes in cancers, with special up-to-date reference to leukemia. Asian Pac J Cancer Prev, 12, 3453-6. |
18 | Movafagh A, Hajifathali A, Isfahani F, et al (2012). Geographic heterogeneity of cytogenetic characteristics of acute myeloid leukemia in the early detection. Iran J Cancer Prev, 2, 85-89. |
19 | Pan G, Ni J, et al (1997). Anantagonist decoyreceptor and a death domain-containing receptor for TRAIL. Science , 277,815-8. DOI |
20 | Pan G, O'Rourke K, et al (1997). The receptor for the cytotoxic ligand Trail. Science , 276,111-3. DOI |
21 | Peto R, Boreham J, et al (2000). UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet, 355, 1822-3. |
22 | Reed JC (2006). Drug insight cacner therapy strategis, based on restoration of endogenous cell death mechanism. Nat clin pract oncol, 3, 388-98. DOI |
23 | Schneider P, Thome M, et al (1997). TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity,7, 831-6. DOI |
24 | Seifi-Alan M, Shamsi R, Ghafouri-Fard S, et al (2014). Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev, 14, 6625-9. |
25 | Shargh SA, Sakizli M, Khalaj V, et al ( 2014) Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol, 31, 250-9. DOI |
26 | Walczak H, Degli-Esposti MA, et al (1997). Trail R2: a novel apoptosis mediating receptor. EMBO,16, 5386-97. DOI |
27 | Wei W, Liu Y, et al (2005). Current understanding on the immunological functions of tumor necrosis factor-related apoptosis-inducing ligand. Cell MolImmunol, 2, 265-9. |
28 | Wiley SR, Schooley K, et al (1995). Identification and characterization of a new member of theTNF family that induces apoptosis. Immunity, 3, 673-82. DOI |
29 | Wu GS, Burns TF, et al (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet, 17, 141-3. DOI |
![]() |